Apyx Medical Story

<div class='circular--portrait' style='background:#FF6600;color: #FFFAFA;font-size:4em;'>AM</div>
APYX -- USA Stock  

USD 7.63  0.07  0.93%

While some traders are getting carried away by overanalyzing healthcare space, it is reasonable to break down Apyx Medical against current market trends. As we have suggested previously, Apyx Medical is beginning its slide as investors shift to be more bearish due to the increased sector volatility. The returns on the market and returns on Apyx Medical appear slightly correlated for the last few months. Strong basic indicators of the company may also suggest signals of long term gains for Apyx Medical investors. Apyx Medical is scheduled to announce its earnings today. The next earnings report is expected on the 15th of March 2021.
Published over two weeks ago
View all stories for Apyx Medical | View All Stories
Will Apyx Medical (NASDAQ:APYX) continue to slide in December?
This firm's average rating is Buy from 3 analysts. Do analysts base this consensus on technical analyses? We know that typical technical analysis utilizes price momentum, patterns, and trends looking at historical prices. It aims to identify signals based on Apyx Medical market sentiment investors' perception of the future value of Apyx Medical. Let us look at a few aspects of Apyx Medical technical analysis. The company has Profit Margin (PM) of (65.13) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (96.54) %, which suggests for every $100 dollars of sales, it generated a net operating loss of -0.97.
Using predictive technical analysis, we will analyze different prices and returns patterns and diagnose historical swings to determine the real value of Apyx Medical. In general, we focus on analyzing Apyx Medical stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Apyx Medical's daily price indicators and compare them against related drivers such as momentum indicators and various other types of predictive indicators. Using this methodology combined with a more conventional technical analysis and fundamental analysis, we attempt to find the most accurate representation of Apyx Medical's intrinsic value. In addition to deriving basic predictive indicators for Apyx Medical, we also check how macroeconomic factors affect Apyx Medical price patterns. Please read more on our technical analysis page or use our predictive modules below to complement your research.

How does Apyx Medical Stands against Peers?

Analyzing Apyx Medical competition or peers my help you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Try to analyze the advantages of investing in traded instruments related to Apyx Medical across multiple sectors and thematic ideas. A good competitive analysis can cover a lot of different areas. But what areas to choose depends on who you are. The more exhaustive you are in your analysis, the more effective your competitive analysis will be.
Check out Apyx Medical Competition Details

How Apyx Medical utilizes its cash?

To perform a cash flow analysis of Apyx Medical, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Apyx Medical is receiving and how much cash it distributes out in a given period. The Apyx Medical cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities. Apyx Medical Net Cash Flow from Operations is fairly stable at the moment as compared to the past year. Apyx Medical reported Net Cash Flow from Operations of (18.48 Million) in 2019

Acquisition by Minnie BaylorHenry of 17000 shares of Apyx Medical subject to Rule 16b-3

Legal trades by Apyx Medical insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Apyx Medical insider trading alert for grant of stock option (option to buy) by Minnie BaylorHenry, the corporate stakeholder, on 10th of August 2020. This event was filed by Apyx Medical Corp with SEC on 2020-08-10. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Closer look at Apyx Medical Mean Deviation

Apyx Medical has current Mean Deviation of 2.46. The mean deviation of the equity instrument is the first measure of the distances between each value of security historical prices and the mean. It gives us an idea of how spread out from the center the distribution of returns.

Mean Deviation is the average of the absolute values of the differences between price distribution numbers and their mean. Mean deviation of equity instrument with a lot of historical data is a biased estimator because the time horizon used in calculation will always be much smaller than the entire price history of the equity. The mean deviation is typically used as a measure of dispersion for small investment horizon, otherwise standard deviation is a better measure of dispersion.

Mean Deviation 
 = 
SUM(RET DEV) 
 = 
2.46
SUM = Summation notation
RET DEV = Sum of return deviations of Apyx Medical
N = Number of calculation points for selected time horizon
Let's now compare Apyx Medical Mean Deviation to its closest peers:
APYX
ECIA
DYNT
EDAP
EW
APYX2.4633920716253446
ECIA4.84
DYNT2.24
EDAP2.69
EW1.51

Will Apyx Medical price slide impact its balance sheet?

Current standard deviation is at 3.16. Apyx Medical currently demonstrates below-verage downside deviation. It has Information Ratio of 0.09 and Jensen Alpha of 0.3. However, we do advice investors to further question Apyx Medical expected returns to ensure all indicators are consistent with the current outlook about its relatively low value at risk.

The Bottom Line

While many other companies in the medical devices industry are either recovering or due for a correction, Apyx Medical may not be as strong as the others in terms of longer-term growth potentials. While some investors may not share our view, we believe it may be a good time to increase your existing holdings in Apyx Medical as the risk-reward trade off is appealing enough to hold a position. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Apyx Medical.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Apyx Medical. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com